Benzinga · Sep 24, 2026
Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and announces $337 price target.
NASDAQ · JAZZ
Jazz Pharmaceuticals plc
Healthcare · Biotechnology
$235.67
Up+$2.66 (+1.14%)
Updated Oct 3, 2026, 5:53 PM
SID Score
5.9/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 10.02B
- P/E ratio
- -27.16
- Dividend yield
- 0.00%
- 52-week range
- $156.95 – $266.38
- Volume
- 638.38K
- Avg. volume
- 1.03M
Price performance · JAZZ
JAZZ price history
1M range · 0 trading sessions · Daily adjusted prices
JAZZ does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest JAZZ news
The latest Smart Investors Daily articles mentioning JAZZ.
Stock researchCompany · Overview
Company
Market Activity
Research & News
JAZZ research
Overview
Company profile and research snapshot.
Company profile
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $190.43
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2026 | Citigroup | Buy | — |
| Sep 24, 2026 | Goldman Sachs | Buy | — |
| Sep 11, 2026 | UBS | Buy | — |
| Sep 10, 2026 | Barclays | Overweight | — |
| Aug 26, 2026 | Morgan Stanley | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 21, 2026
Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development
Iambic Therapeutics, an AI drug discovery company backed by Nvidia and the Qatar Investment Authority, filed to go public Monday.
Yahoo · Sep 20, 2026
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B
Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference. Chumi Khurana, senior vice president of U.S. Oncology
Yahoo · Sep 18, 2026
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?
Actio could make Jazz's growing epilepsy franchise even stronger.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
